Gait variability in patients with COPD during a self-paced 6-minute walk test

W.Y. Liu\textsuperscript{1,2}, M.A. Spruit\textsuperscript{1,4}, J.M. Delbressine\textsuperscript{1}, P.J. Willems\textsuperscript{2}, F.M.E. Franssen\textsuperscript{1,3,4}, E.F.M. Wouters\textsuperscript{1,3}, K. Meijer\textsuperscript{2}

\textsuperscript{1}Department of Research and Education, CIRO, Horn, the Netherlands. \textsuperscript{2}Department of Human Movement Science, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, the Netherlands. \textsuperscript{3}Department of Respiratory Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands. \textsuperscript{4}Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, the Netherlands.

\textbf{Background & aim}
Patients with chronic obstructive pulmonary disease (COPD) have an increased falls risk [1] and demonstrate gait deficits [2,3]. Gait variability has been associated with increased risk for falls in the aging population [4]. However, studies reporting gait variability in COPD are scarce. Gait variability could be assessed during commonly used exercise test in pulmonary rehabilitation, such as the 6-minute walk test (6MWT). Therefore, we aim to assess gait variability in COPD patients during the 6MWT.

\textbf{Materials and methods}
80 COPD patients (48 males; 62±7 yrs.; FEV\textsubscript{1}:56±19 %pred.) and 39 healthy subjects (25 males; 62±6 yrs.; FEV\textsubscript{1}:119±17 %pred.) performed two self-paced 6MWTs on the Gait Real-time Analysis Interactive Lab, while kinematic parameters were recorded (100Hz, Vicon Nexus). The largest walk distance was used for analysis. The amount (coefficient of variation; CoV) and structure (sample entropy) of variability of stride time, stride length and step width, and local divergence exponent of the centre of mass velocity (COM\textsubscript{v}) in mediolateral, anteroposterior and vertical direction were computed from 444 steps. Sub-analysis was performed to account for gait speed influences on gait variability between the groups.

\textbf{Results}
COPD patients achieved 497±79 m and controls 691±64 m. Stride time was higher (MD: 0.13 s, p<0.001) and stride length was smaller (MD:-0.30 s, p<0.001) in COPD. CoV for stride length was increased (MD: 1.8\%, p<0.001) and sample entropy of stride length was lower in COPD (MD: 0.21, p<0.001, Fig 1). Local divergence exponent for COM\textsubscript{v} differed in vertical (MD: -0.12, p=0.001) and anteroposterior direction (MD: 0.10, p=0.017).

Differences in CoV for stride length remained higher in COPD (MD: 1.0 \%, p=0.003) and sample entropy for stride length remained lower in COPD (MD: -0.12, p=0.011), after a sub-analysis of 14 patients and 14 healthy subjects with comparable walking speeds (MD: -0.02 m/s, p=0.588). Local divergence exponents for COM\textsubscript{v} did not differ between the groups in the sub-analysis.

\textbf{Conclusion}
COPD patients demonstrate alterations in the amount and structure of variability in stride length. These findings indicates alterations in the control of stride length variability pattern and might represent a lack of adaptability during walking as compared to healthy subjects. However, the local stability of the centre of mass was not altered in patients with COPD.
References

**Fig 1.** Variability in stride length for patients with COPD and healthy subjects. Upper left: CoV for stride length in total sample. Upper right: CoV for stride length in the subanalysis. Lower left: sample entropy for stride length in total sample. Lower right: sample entropy for stride length in the subanalysis.